Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06973109) titled 'Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes' on May 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).
Primary Sponsor: Nitin Agarwal
Condition:
Osteoporosis, Post-menopausal
Intervention:
Drug: Romosozumab
Drug: Alendronate (Fosamax)
Drug: Placebo Romosozumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 2025
Target Sample Size: 36
Countries of Recruitment:
United States
To know more, visit https://clinic...